As many as 12 institutes, including one from Odisha have been selected by ICMR for the clinical trial of the country’s first indigenous COVID-19 vaccine, an official said recently.

Bhubaneswar-based Institute of Medical Sciences and SUM Hospital under the SOA Deemed to be University, has been chosen by the Indian Council for Medical Research (ICMR) for undertaking human clinical trials of India’s first coronavirus vaccine, an official of the institute was quoted saying by a PTI report.

ICMR has developed the indigenous COVID-19 vaccine (BBV152 COVID vaccine) partnered with Bharat Biotech International Limited (BBIL). The 12 institutes have been asked by the ICMR to fast track clinical trials of the vaccine as it is being considered as one of the top priority projects which are being monitored at the topmost level of the government.

Also read: ICMR to scale up COVID-19 testing capacity to 4 lakh per day

“The vaccine is derived from a strain of SARS-CoV-2 isolated by ICMR-National Institute of Virology, Pune. ICMR and BBIL are jointly working for the pre-clinical as well as clinical development of this vaccine,” an official said.

In a letter to the selected institute where the clinical trial is to be done, the ICMR also informed that it is envisaged to launch the vaccine for public health use latest by August 15, 2020 after completion of all clinical trials.

Apart from IMS and SUM Hospital, the other institutes selected for the clinical trial are located in Visakhapatnam, Rohtak, New Delhi, Patna, Belgaum (Karnataka), Nagpur, Gorakhpur, Kattankulathur (Tamil Nadu), Hyderabad, Arya Nagar, Kanpur (Uttar Pradesh) and Goa, the report said.

Like

Dislike

Be a part of Elets Collaborative Initiatives. Join Us for Upcoming Events and explore business opportunities. Like us on Facebook , connect with us on LinkedIn and follow us on Twitter , Instagram.